Site Search
Displaying results 401 - 410 of 573
Resource | Publications,
Over the past 13 years, the MSF Access Campaign has been monitoring the patent barriers, prices and availability of ARVs through Untangling the Web and pushing for the uptake of policies that promote access to affordable quality medicines. Due primarily to generic competition, the price of ARVs has dropped by more than 99% over the last decade, but the price of the newest drugs, already needed by some people in MSF projects, is prohibitive and a source of great concern both for MSF and for national treatment programmes.
Resource | Videos,
Tracking the HIV/AIDS Epidemic in Asia and the Pacific from AIDS Data Hub on Vimeo.
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
By Mr. J.V.R. Prasada Rao United Nations Secretary-General’s Special Envoy for AIDS in Asia and the Pacific
3 July 2013 Kuala Lumpur, Malaysia
Resource | Videos,
Video of the presentation by By Mr. J.V.R. Prasada Rao United Nations Secretary-General’s Special Envoy for AIDS in Asia and the Pacific, at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Resource | Guidelines,
These consolidated guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, care and treatment. Behavioural, structural and biomedical interventions that do not involve the use of ARV drugs are not covered in these guidelines.
The 2013 consolidation process combines and harmonizes recommendations from a range of WHO guidelines and other documents, including the following 2010 guidelines on using antiretroviral therapy (ART) for HIV infection in adults and adolescents, in infants and children and for treating pregnant women living with HIV and preventing HIV infection in infants. Comprehensive guidance is now provided on using ARV drugs across age groups and populations of adults, pregnant and breastfeeding women, adolescents, children and key populations. The guidelines also aim to consolidate and update clinical, service delivery and programmatic guidance.
Resource | Publications,
This publication reports on the progress being made in the global scale-up in the use of antiretroviral (ARV) medicines in low- and middle-income countries, the challenges that are being overcome or that await solutions and the opportunities for building on the achievements of the past decade.
Resource | Publications,
With this new Strategy 2013-2016, UNITAID enters what could be called the third stage of its
development.
UNITAID's mission has remained constant over the years. It increases access to treatment for HIV/
AIDS, TB and malaria for people in developing countries by leveraging price reductions of quality drugs and diagnostics, which currently are unaffordable for most developing countries, and to accelerate the pace at which they are made available.
The UNITAID Strategy 2013-2016 provides an excellent vision that will guide new investments. It
identifies the tools needed to implement the Strategy, of which many are already under development,
tried and tested. UNITAID remains creative in its approach, and is ready and able to develop new tools or engage in new partnerships that will ensure its objectives are met. UNITAID’s innovative source of income will continue to be well invested, and UNITAID will strive to increase its funding capacity through new and existing donors.
Resource | Publications,
The present report focuses on certain forms of abuses in health-care settings that may cross a threshold of mistreatment that is tantamount to torture or cruel, inhuman or degrading treatment or punishment. It identifies the policies that promote these practices and existing protection gaps.
By illustrating some of these abusive practices in health-care settings, the report sheds light on often undetected forms of abusive practices that occur under the auspices of health-care policies, and emphasizes how certain treatments run afoul of the prohibition on torture and ill-treatment. It identifies the scope of State's obligations to regulate, control and supervise health-care practices with a view to preventing mistreatment under any pretext.
Resource | Publications,
The purpose of the Discussion Paper is to facilitate the UNDP consultation on enforcement of intellectual property rights, in particular anti-counterfeit measures and access to HIV treatment and other essential medicines in sub-Saharan Africa. The Discussion Paper summarizes the developments in intellectual property rights enforcement in the world and in the region. It elaborates on the public health impact of anti-counterfeit laws and discusses whether they are an adequate solution to the legitimate concerns about the quality, safety and efficacy of medicines. The Discussion Paper explores the impact of such laws on the spread of substandard and falsified medicines compared to their impact on good-quality generic medicines, which are essential for the public health systems of most African countries.
The Discussion Paper explores model provisions for the definition of ‘counterfeiting’, criminal liability, powers of seizure and storage, goods in transit, rules on evidence and presumptions and liability for loss of or damage to goods. Discussions of the model provisions evolve around the public health priorities of African countries, and the need to avoid conflation between good-quality generics and substandard and falsified medicines.
Resource | Publications,
Over the past ten years, an increasing number of countries are initiating, negotiating and agreeing new trade agreements between two countries or amongst a group of countries. These are commonly known as free trade agreements or "FTAs", and they are promoted as providing significant economic benefits to signatory countries through the removal or reduction of barriers to trade in goods and services. Many political leaders have indicated that they would prefer to remove or reduce trade barriers through the multilateral system in a way that benefits all countries belonging to the World Trade Organization. Nevertheless, given that the "Doha Round" of negotiations is taking longer than initially anticipated to be concluded, bilateral and regional FTAs are often seen as a way to move forward the trade liberalization agenda in the meantime.